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Abstract
Piergiuseppe Agostoni. Considerations on safety and treatment of patients with chronic heart failure at high
altitude. High Alt Med Biol 14:96–100, 2013.—Prognosis and quality of life of chronic heart failure (HF) patients
have greatly improved over the last decade. Consequently, many patients are willing to spend leisure time at
altitude, usually < 3500 m, but their safety in doing so is undefined. HF is a syndrome that often has relevant co-
morbidities, such as pulmonary hypertension, COPD, unstable cardiac ischemia, and anemia. HF co-morbidities
may per se impede a safe stay at altitude. Exercise at simulated altitude is associated with a reduction in
performance, which is greater in HF patients than in normal subjects and greater in patients with most severe HF.
In normal subjects, the reduction in performance is*2% every 1000 m altitude increase, whereas it is 4% and 10%
in HF patients with normal or slightly diminished exercise capacity and in HF patients with markedly diminished
exercise capacity. On-field experience with HF patients at altitude is limited to subjects driven to altitude (3454 m)
for a few hours. The data showed a reduction in exercise capacity similar to that reported at simulated altitude.
‘‘Optimal’’ HF treatment in patients spending time at altitude is likely different from optimal treatment at sea
level, particularly as regards b-blockers. Carvedilol, a b1–b2-a-blocker, reduces the hypoxic ventilatory response
through a reduction of the chemoreflex response, and it reduces alveolar-capillary gas diffusion, which is under
control by b2-receptors. These actions are not shared by selective b1-blockers such as bisoprolol and nebivolol,
which should be preferred for treatment of HF patients willing to spend time at altitude. In conclusion, spending
time at altitude (< 3500 m) is safe for HF patients, provided that subjects are free of co-morbidities that may
directly interfere with the adaptation to altitude. However, HF patients experience a reduction of exercise capacity
in proportion to HF severity and altitude. Finally, HF patients should undergo a specific ‘‘altitude-tailored
treatment’’ to avoid pharmacological interference with altitude adaptation mechanisms.
Introduction
Chronic heart failure (HF) is among the most frequentdiseases in western countries, with 670,000 new cases a
year in the US (Lloyd-Jones et al., 2010). Both survival and
quality of life of HF patients significantly improved in the last
decades, mainly due to an improvement in therapies. Con-
sequently, many HF patients have a normal or almost normal
life for a prolonged time, which may include the chance of
spending leisure time at altitude. This usually means an alti-
tude between 1000 and 3500 m.Questions that are often not
easy to answer are whether staying at high altitude is safe for
HF patients, whether all patients behave in the same way at
altitude, or whether there are differences among patients at
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altitude with respect to HF severity and co-morbidities, and,
finally, whether HF patients should adapt their physical
performance at altitude. Moreover, it is unclear whether,
among the different HF therapeutic strategies available, there
is one most appropriate for subjects who plan an altitude
sojourn.
Chronic HF is a syndrome which is characterized by the
impairment of several body parts, such as lungs, kidney,
muscles, pulmonary circulation, red blood cells, and sympa-
thetic nervous system, all of which imply a specific adaptation
to altitude or may be further impaired at altitude. Moreover,
HF patients frequently have co-morbidities, such as—just to
mention some—lung diseases, systemic hypertension, meta-
bolic syndrome, peripheral and coronary vascular diseases,
all of which may have a detrimental role in altitude adapta-
tion, particularly when combined with HF. Therefore, patients
with HF and lung disease, pulmonary hypertension—including
out-of-proportion pulmonary hypertension due to HF
(Simonneau et al., 2009)—anemia, severe renal insufficiency,
angina, or primitive cardiac valvular or pericardial diseases,
who are willing to ascend to altitude, should be evaluated for HF
and also for the specific HF co-morbidities they are affected by.
For instance, in a patient with HF and COPD, the latter is the
factor that actually limits altitude exposure due to a greater ar-
terial Po2 reduction compared to non-COPD HF subjects (Gong
et al., 1984; Gong, 1989). A counterproof of this is the observation
that, among HF patients exposed to low altitude (below sea level
as in the Dead Sea), patients with HF and COPD (with exercise-
induced arterial desaturation) improve exercise performance
more than HF patients without COPD (Abinader et al., 1999).
Several physiological adaptations to or consequences of
high altitude exposure may, in principle, negatively influence
the physical condition of HF patients, which includes the in-
crease of sympathetic activity, pulmonary and systemic blood
pressure, heart rate, lung fluid content, or the reduction of
stroke volume (Agostoni et al., 2009; Cogo and Miserocchi,
2011; Rimoldi et al., 2010; Swenson, 2011). Some of these ef-
fects are limited in time but, because they are possibly asso-
ciated with a deterioration of HF, they should be cautiously
considered when evaluating whether a HF patient can go to
high altitude. Therefore, at first glance, HF patients should be
advised to not go to altitude, albeit it has been very recently
suggested that repeated, short-lasting (3–4 hours) exposures
to a simulated altitude up to 2700 m may be beneficial for
HF patients in terms of quality of life, muscular strength,
and exercise performance (Saeed et al., 2012). However, a
3–4-hour exposure may be different from a 24-hour or longer
exposure, because the negative effects of some adaptations to
high altitude may need more time to develop completely.
Very few non-laboratory, real-life experiences are presently
available for HF patients at altitude. Indeed, albeit laboratory
studies are able to mimic hypoxic conditions, this is not the
case for other variables encountered at altitude, such as a cold
and dry environment, as well as poor weather conditions in
general. Exercising in a cold and dry environment does imply
a greater energy consumption if compared to exercise per-
formed in a comfortable setting. However, it is now appreci-
ated that patients with coronary artery disease and preserved
left ventricular function can safely reach altitude and exercise
there, and that adverse cardiac events, such as unstable an-
gina or coronary syndrome, do not occur more frequently
than at sea level if subjects unaccustomed to exercise are ex-
cluded (Dehnert and Bartsch, 2010; Schmid et al., 2006; de
Vries et al., 2010). Indeed, Schmid et al. (2006) showed that
coronary patients who have been completely revascularized
can safely go and exercise at the Jungfraujoch (3454 m), and de
Vries et al. (2010) showed that patients with a history of
myocardial infarction and preserved left ventricular function
presented a decrease in exercise capacity similar to that
of healthy controls at 4200 m in the Aconcagua region after a
10-day acclimatization (de Vries et al., 2010). No data are
available for HF patients, except for another study of the
Schmid group (Nobel et al., 2010), which showed that HF
patients in stable clinical condition, class NYHA II, and with
peak Vo2 at 540 m > 50% of that predicted, can safely reach
and exercise at the Jungfraujoch (3454 m). In these HF
patients, peak Vo2 decreased by 22% at altitude, and no
significant changes were observed in the arrhythmic pattern
as well as in echocardiographic measurements, except for an
increase in pulmonary pressure. However, it should be no-
ticed that, in the study by Schmid, HF patients reached the
Jungfraujoch by cable car and remained at 3454 m for only few
hours. Both the absence of a significant effort to reach altitude
and the short-lasting altitude exposure may have contributed
to the positive results reported by Schmid. As a matter of fact,
a significant effort is associated to lung fluid accumulation as
a few day stay at altitude is (Agostoni et al., 2009; Heath and
Williams, 1981; Singh et al., 1965).
Several HF patients have implanted defibrillators (ICD) for
arrhythmia treatment, and several have pacemaker-mediated
resynchronization therapy (CRT) for HF treatment. At pres-
ent, little information exists regarding function of ICD and
CRT at altitude. Weilenmaen et al. (2000) studied 13 patients
with single chamber pacemakers and found no changes in
ventricular stimulation thresholds at a simulated altitude of
4000 m, although the duration of exposure was only 30 min
and may not accurately reflect what would happen with
longer stays in hypobaric hypoxia. Moreover, in a recent
survey study in Swiss patients living at altitude, it has been
reported that ICD shock was rare (4%) and it has been sug-
gested that ICD patients living at moderate altitude may
safely perform moderate physical activity (Kobza et al., 2008).
More precise information is available regarding exercise
performance in HF patients during exposure to acute hypoxia
as obtainable in a laboratory setting. Indeed, exercise perfor-
mance was progressively reduced in HF patients if they ex-
ercised at a simulated altitude of 1000, 1500, 2000, and 3000 m
(Fig. 1). Notably, this reduction was greater in HF patients
than in normal subjects, and it was greater in the more severe
HF patients (Agostoni et al., 2000), where the severity of the
disease was defined by peak Vo2 (normal exercise perfor-
mance: peak Vo2> 20 mL/min/kg, slightly diminished exer-
cise capacity: peak Vo2 between 20 and 15 mL/min/kg, and
markedly diminished exercise capacity: peak Vo2 < 15 mL/
min/kg). As an average, we observed an exercise capacity
reduction of *2%, *4%, and *10% every 1000 m altitude
increase in normal subjects, HF patients with normal or
slightly diminished exercise capacity, and HF patients with
markedly diminished exercise capacity, respectively. These
data are in line with Schmid’s findings at the Jungfraujoch
(Nobel et al., 2010). Moreover, it is important to observe that
alveolar capillary gas diffusion correlates with exercise per-
formance in HF both at sea level (Agostoni et al., 2006a) and at
simulated altitude (Agostoni et al., 2002b), and that alveolar
capillary gas diffusion during exercise increases in healthy
subjects, is unchanged in patients with moderate HF, and
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decreases in patients with severe HF (Agostoni et al., 2003;
Cattadori et al., 2009). Alveolar capillary gas diffusion nega-
tively correlates with the widening of the alveolar-capillary
Po2 gradient at peak exercise both in normoxic and hypoxic
exercise (Agostoni et al., 2002b). Interestingly, HF patients
who are able to increase alveolar capillary diffusion during
light exercise are those who showed a lowest exercise per-
formance reduction at a 2000 m simulated altitude (Fig. 2)
(Agostoni et al., 2002b). The bulk of the above-reported in-
formation suggests that alveolar capillary gas diffusion at rest
and its changes during exercise influence the exercise per-
formance of HF patients in hypoxic conditions.
It should also be noticed that we have no data on the effects
of prolonged altitude sojourns for HF patients. Indeed, alti-
tude adaptation includes, in healthy subjects, among others,
improvement of ventilation, alveolar capillary diffusion, and
oxygen carrying capacity in the blood. All these should in-
crease exercise performance of HF patients. Similarly we have
no data to answer the frequently asked question on how fast a
HF patient can safely travel to altitude, including rate of as-
cent and staging at intermediate altitude. Consequently,
cautious advice should be given to HF patiens willing to
spend prolonged time at altitude.
All the above-reported data, either at simulated or at real
altitude, have been obtained in HF patients in stable clinical
conditions and on so-called optimal medical treatment. The
latter is defined at sea level, but the optimal medical treatment
for a given HF patient may be different at altitude. Two factors
among several others that influence exercise performance at
altitude, and precisely the alveolar capillary gas diffusion and
the chemoreflex-mediated ventilatory response to hypoxia,
are impaired in HF and, most importantly, they can be di-
rectly influenced by drugs used for HF treatment. Indeed, ion
transport and the accompanying fluid movement across the
alveolar capillary membrane are active phenomena under
the control of b2 receptors located on the airway surface of
type I and II alveolar cells, and chemoreflex is regulated by
angiotensine, nitric oxide, b1, b2 and a receptors. Angio-
tensine 1 (AT1) receptor blockers and b-blockers are among
the drugs used for the treatment of HF. The high-altitude
adaptation of a normal subject on AT1 receptor blockers
(telmisartan) is the main topic of an extensive research pro-
ject, the HIGHCARE project, which was recently conducted
at the Mount Everest South Base Camp (5400 m). No result
on the effect of telmisartan on ventilatory and blood pressure
control at high altitude has been released yet. Differently, it
is now appreciated that the exercise performance of healthy
subjects at high altitude is influenced by the type of b-blocker
used. In a recent report, Valentini et al. (2011) showed that at
Capanna Regina Margherita (4560 m) peak Vo2 was lower in
healthy subjects treated with carvedilol (b1-b2 receptor
blocker) than in those on nebivolol (a selective b1 receptor
blocker). This difference was related to a greater peak exer-
cise ventilation at altitude with nebivolol versus carvedilol.
Finally, some preliminary data by our group on the effects of
acetazolamide at high altitude indicate that this drug may be
particularly useful at altitude in HF patients, albeit the op-
posite happens at sea level (Apostolo et al., 2008).Indeed,
acetazolamide seems to prevent the lung fluid accumulation
observed at altitude and to counteract altitude-induced lung
diffusion reduction (Agostoni et al. 2013).
Some studies have been carried out by our group in Milan
to assess the effects of HF treatment on exercise performance
FIG. 2. Reduction of exercise capacity in hypoxia. DW/W=
[maximum workload achieved in normoxia - maximum
workload achieved in hypoxia]/maximum workload
achieved in normoxia. DTLCO =differences in lung diffusing
capacity for carbon monoxide between the fifth minute of
exercise and rest in heart failure patients. Patients with the
greatest capability to increase TLCO during exercise are
those who show the smallest reduction in exercise capacity in
hypoxia. From Agostoni et al., 2002b.
FIG. 3. Effect of carvedilol (filled symbols) versus placebo
(empty symbols) on ventilation at different work rates, both in
normoxic (circles) and in hypoxic (squares) conditions. Data
from Agostoni et al., 2006b.
FIG. 1. Mean ( – 95% confidence intervals) reduction in
maximum work rate with simulated altitude, as a percentage
decrease from maximum work rate at 92 m. Slopes differed
( p< 0.05) in healthy subjects (-2% – 1% per 1,000 m; filled
squares) compared with patients, and between patients with
normal (-4– 2%; filled circles), or slightly diminished work-
load (-4– 2%; filled triangles) compared with patients with
markedly diminished workload (-10 – 3%; open circles). From
Agostoni et al., 2000.
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of patients at a simulated altitude of 2000 m (Agostoni et al.,
2002a; 2002b; 2007). This altitude was chosen because it is
likely to be reached by HF patients during leisure time in the
mountains. Two issues were analyzed: the effects of different
b-blockers on alveolar capillary gas diffusion and those on the
regulation of ventilation during exercise. As regards their ef-
fects on alveolar capillary gas diffusion, chronic carvedilol
treatment is associated to a reduction of total alveolar cap-
illary diffusion, as inferable from DLCO measurement
(Agostoni et al., 2002a). By splitting DLCO into its two com-
ponents, membrane diffusion and capillary volume, we
showed that carvedilol reduced the former. We then showed
that DLCO was reduced in HF patients on carvedilol, but not
in those on bisoprolol (Agostoni et al., 2006b), and that this
reduction directly correlated with a reduction of exercise
performance in HF patients with DLCO < 80% of its predicted
value (Agostoni et al., 2007). We very recently (Contini et al.,
2012) confirmed this observation in a cross-over study com-
paring HF patients on carvedilol, bisoprolol, and nebivolol,
the CARNEBI trial, and we showed that the reduction in
DLCO was only observed during treatment with carvedilol.
Interestingly, the reduction in DLCO was associated to an
increase of the alveolar capillary po2 gradient, confirming the
physiological significance of an even modest reduction in
DLCO. Ventilation is regulated by several factors, including
chemoreceptors. Chemoreceptor response in HF is increased
as a part of the increased sympathetic tone, and this is one of
the reasons why ventilation efficiency is reduced during ex-
ercise in HF. This reduction has a significant prognostic role
(Gitt et al., 2002; Guazzi et al., 2008). Ventilation efficiency
during exercise is usually assessed by the analysis of the
ventilation to Vco2 relationship, which increases in case of in-
efficiency. Carvedilol reduces ventilation at a given work rate
both in normoxic and hypoxic conditions (Fig. 3) (Agostoni
et al., 2006b). This reduction is associated with a lower Pao2
(Agostoni et al., 2006b). This is not the case for bisoprolol and
nebivolol (Agostoni et al., 2002a; 2010). Albeit a reduction of
the ventilation to Vco2 relationship at sea level is likely to be a
positive event, the opposite is probably true at altitude, being
the ventilatory response necessary to counterbalance the ef-
fects of a reduced inspired po2. In the CARNEBI trial, we
showed that carvedilol is the b-blocker that most reduces the
chemoreceptor response to hypoxia and hypercapnia (both
central and peripheral). The bulk of the above-reported
studies indicates that a b1 selective blocker, either bisoprolol
or nebivolol, should be preferred to a b1-b2 blocker, such as
carvedilol, for treating HF patients who are expected to spend
time at altitude. It should be acknowledged, however, that we
have no data as regards the effect of prolonged hypoxia ex-
posure, as during a long sojourn at altitude, in HF patients
with different betablocker treatments.
In conclusion, HF patients can safely spend leisure time at
altitude up to 3500 m, provided that they are on optimal,
‘‘altitude-tailored’’ HF treatment. HF patients, however,
should expect a reduction of physical performance in rela-
tionship to the severity of the disease and to the altitude they
will reach. Patients with HF co-morbidities should be evalu-
ated with care, because the co-morbidities may definitively
preclude HF patients from safely staying at altitude.
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